Your doctor will also likely delve into the nitty-gritty on those symptoms to get a better sense of the issue. As Dr. Moldwin ...

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating ...

Drug-loaded contact lenses have been studied ... and reduced reliance on patient adherence to multiple daily eye drop instillation. For practicing optometrists, these findings are significant ...

Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing ...

ImmunityBio, Inc. faces stock decline amid fundraising and market selloff. Click to read more on the long-term potential of ...

Reproxalap was safe and well-tolerated, with mild instillation site discomfort as the most common adverse event. The topical ocular drug is an investigational new drug candidate that requires more ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration ... Administer ADSTILADRIN by intravesical instillation only.

By 2022, the United States is predicted to hold 87.9% of the market for postoperative pain in North America. It is anticipated that the adoption of opioid treatment will slow the opioid epidemic’s ...

Despite quitting her habit nine months a go, she's been left with irreversible damage to her organs. Specifically, her bladder has been practically destroyed.

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients ...